• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Minimal residual disease in chronic myeloid leukemia.

作者信息

Löwenberg Bob

机构信息

Erasmus University Medical Center, Rotterdam, The Netherlands.

出版信息

N Engl J Med. 2003 Oct 9;349(15):1399-401. doi: 10.1056/NEJMp038130.

DOI:10.1056/NEJMp038130
PMID:14534331
Abstract
摘要

相似文献

1
Minimal residual disease in chronic myeloid leukemia.慢性髓性白血病中的微小残留病
N Engl J Med. 2003 Oct 9;349(15):1399-401. doi: 10.1056/NEJMp038130.
2
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.新诊断慢性髓性白血病患者对伊马替尼或干扰素α加阿糖胞苷产生主要分子反应的频率。
N Engl J Med. 2003 Oct 9;349(15):1423-32. doi: 10.1056/NEJMoa030513.
3
Residual disease in chronic myeloid leukemia after induction of molecular remission.
N Engl J Med. 2003 Oct 9;349(15):1483-4. doi: 10.1056/NEJM200310093491521.
4
[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].[慢性髓性白血病患者微小残留病的监测：实时聚合酶链反应的临床价值]
Ter Arkh. 2007;79(4):49-53.
5
[Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Dtsch Med Wochenschr. 2006 Oct 27;131(43):2390-4. doi: 10.1055/s-2006-955020.
6
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].[通过实时定量逆转录聚合酶链反应检测和定量慢性髓性白血病患者的BCR-ABL转录本]
Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):453-7.
7
Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
N Engl J Med. 2002 Aug 15;347(7):539-40. doi: 10.1056/NEJM200208153470719.
8
[Chronic myeloid leukemia].
Dtsch Med Wochenschr. 2011 Oct;136(40):2007-10. doi: 10.1055/s-0031-1286381. Epub 2011 Sep 28.
9
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.一名同时表达p190（BCR-ABL）癌蛋白和JAK2V617F突变的慢性髓性白血病患者对伊马替尼的反应
Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.
10
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.在e1a2 BCR-ABL慢性髓性白血病中，尽管对伊马替尼的分子反应未达最佳，但仍实现持续临床缓解。
Leuk Res. 2010 Jul;34(7):e176-7. doi: 10.1016/j.leukres.2010.01.025. Epub 2010 Feb 12.

引用本文的文献

1
Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.实时定量聚合酶链反应：慢性髓细胞白血病“微小残留病”评估的可靠分子诊断和随访工具。
Biosci Rep. 2018 Oct 5;38(5). doi: 10.1042/BSR20180974. Print 2018 Oct 31.
2
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.Sipa1基因缺陷会引发一种宿主免疫机制，从而根除慢性粒细胞白血病起始细胞。
Nat Commun. 2018 Mar 2;9(1):914. doi: 10.1038/s41467-018-03307-8.
3
MUC1 in hematological malignancies.
血液系统恶性肿瘤中的MUC1
Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27.
4
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.分子动力学揭示 BCR-ABL1 多突变体是对泛 BCR-ABL1 激酶抑制剂治疗产生耐药性的独特机制。
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5. doi: 10.1073/pnas.1321173111. Epub 2014 Feb 18.
5
Interpretation of cytogenetic and molecular results in patients treated for CML.解读 CML 患者的细胞遗传学和分子学结果。
Blood Rev. 2011 May;25(3):139-46. doi: 10.1016/j.blre.2011.02.001. Epub 2011 Mar 17.
6
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.接受酪氨酸激酶抑制剂治疗的伴有多个 ABL1 激酶结构域突变的慢性髓性白血病患者的结局。
Haematologica. 2011 Jun;96(6):918-21. doi: 10.3324/haematol.2010.039321. Epub 2011 Feb 28.
7
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.早期慢性期慢性髓性白血病微小残留病的免疫调节：一线高剂量甲磺酸伊马替尼联合或不联合聚乙二醇干扰素 α-2b 和粒细胞-巨噬细胞集落刺激因子治疗的随机试验。
Cancer. 2011 Feb 1;117(3):572-80. doi: 10.1002/cncr.25438. Epub 2010 Sep 30.
8
Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.伊马替尼治疗慢性髓性白血病时的策略性治疗中断。
Bull Math Biol. 2011 May;73(5):1082-100. doi: 10.1007/s11538-010-9553-0. Epub 2010 Jun 9.
9
The CML stem cell: evolution of the progenitor.慢性粒细胞白血病干细胞：祖细胞的演变
Cell Cycle. 2009 May 1;8(9):1338-43. doi: 10.4161/cc.8.9.8209. Epub 2009 May 17.
10
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.蛋白酪氨酸磷酸酶受体型O（PTPROt）可使致癌融合蛋白BCR/ABL失活，并抑制K562细胞的转化。
J Biol Chem. 2009 Jan 2;284(1):455-464. doi: 10.1074/jbc.M802840200. Epub 2008 Nov 7.